Loading clinical trials...
Loading clinical trials...
A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 3 Trial Evaluating the Efficacy and Safety of Felzartamab in Kidney Transplant Recipients With Late Antibody-Mediated Rejection (AMR)
Conditions
Interventions
Felzartamab
Placebo
Locations
59
United States
University of Southern California
Los Angeles, California, United States
Cedars-Sinai Medical Center
Los Angeles, California, United States
UCLA
Los Angeles, California, United States
Providence Healthcare
Orange, California, United States
Loma Linda
San Bernardino, California, United States
California Pacific Medical Center
San Francisco, California, United States
Start Date
December 3, 2024
Primary Completion Date
December 1, 2026
Completion Date
June 1, 2027
Last Updated
March 12, 2026
NCT05004493
NCT04561986
NCT07316829
NCT03719339
NCT03380962
NCT05184426
Lead Sponsor
Biogen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions